IL-21 is required to control chronic viral infection - PubMed (original) (raw)
IL-21 is required to control chronic viral infection
Heidi Elsaesser et al. Science. 2009.
Erratum in
- Science. 2009 Aug 21;325(5943):946
Abstract
CD4+ and CD8+ T cell functions are rapidly aborted during chronic infection, preventing viral clearance. CD4+ T cell help is required throughout chronic infection so as to sustain CD8+ T cell responses; however, the necessary factor(s) provided by CD4+ T cells are currently unknown. Using a mouse model of chronic viral infection, we demonstrated that interleukin-21 (IL-21) is an essential component of CD4+ T cell help. In the absence of IL-21 signaling, despite elevated CD4+ T cell responses, CD8+ T cell responses are severely impaired. CD8+ T cells directly require IL-21 to avoid deletion, maintain immunity, and resolve persistent infection. Thus, IL-21 specifically sustains CD8+ T cell effector activity and provides a mechanism of CD4+ T cell help during chronic viral infection.
Figures
Fig. 1
IL-21 mRNA expression during viral infection. IL-21 mRNA expression was quantified by real-time reverse transcription polymerase chain reaction after LCMV-Arm or LCMV–Cl 13 infection in (A) uninfected (gray bar), LCMV–Cl 13 infected (black bar), or LCMV–Cl 13 infected and CD4+ T cell–depleted (striped bar) splenocytes or in (B) the indicated sorted cell population. Red Bars indicate cells sorted from LCMV-Arm–infected animals; black bars indicate cells sorted from LCMV–Cl 13–infected animals. (C) Frequency of IFN-γ+ SMARTA T cells that simultaneously produced IL-2 or IL-21 on day 9 and day 30 after infection. Error bars represent the average ± SD of 3 to 5 mice per group and 2 to 4 independent experiments. *P < 0.05, **P = 0.4.
Fig. 2
IL-21 sustains virus-specific CD8+ T cells during viral persistence. (A) LCMV-GP33–41 MHC class I tetramer staining on days 9 or 30 after LCMV-Arm or LCMV–Cl 13 infection. Numbers indicate the frequency of tetramer+ CD8+ T cells in WT and _Il21r_−/− (KO) mice. (B) Number of tetramer+ CD8+ T cells on days 9 and 30 after LCMV-Arm or LCMV–Cl 13 infection of WT and _Il21r_−/− mice. (C) Number of WT or _Il21r_−/− P14 T cells after infection of Il21r+/+ mice. (D) Frequency of WT and _Il21r_−/− LCMV-GP33–41 tetramer+ CD8+ T cells in bone-marrow chimeric mice on days 8 and 28 in the blood and on day 28 in the spleen after LCMV–Cl 13 infection. Numbers in parentheses indicate the total proportion of WT and _Il21r_−/− CD8+ T cells. Bar graphs represent the average ± SD of 3 to 5 mice per group and represent 2 to 4 independent experiments. *P<0.05.
Fig. 3
IL-21 suppresses CD4+ T cell function. (A) LCMV-GP61–80–specific CD4+ T cell responses on days 9 and 30 after LCMV-Arm or LCMV–Cl 13 infection of WT or _Il21r_−/− mice. Numbers in each quadrant indicate the frequency of IFN-γ+ and IL-2+ CD4+ T cells and the numbers in parentheses indicate the frequency of IFN-γ and IL-2 double-positive cells. (B) The frequency and number of CD4+ T cells that simultaneously produce IL-2 and IFN-γ on days 9 or 30 after LCMV-Arm or LCMV–Cl 13 infection. (C) Frequency of LCMV-GP61–80 tetramer+ CD4+ T on day 30 after LCMV-Arm or LCMV–Cl 13 infection. The bar graph represents the number of tetramer+ CD4+ T cells. Bar graphs summarize the average ± SD of 3 to 4 mice per group and 3 to 4 independent experiments. *P < 0.05.
Fig. 4
IL-21 is required to purge chronic viral infection. (A) Serum viral titers after LCMV-Arm (triangles) or LCMV–Cl 13 (circles) infection of WT (black) or _Il21r_−/− (red) mice. Data are expressed as plaque-forming units (PFU) per milliliter of serum. The dashed line indicates the lower limit of detection (200 PFU/ml). *P < 0.05 for LCMV–Cl 13 infection of WT versus _Il21r_−/− mice. (B and C) The frequency and number of (B) LCMV-GP33–41 tetramer+ CD8+ T cells and (C) IFN-γ+ CD4+ T cells on day 100 after LCMV–Cl 13 infection of WT and _Il21r_−/− mice. Time points and bar graphs represent the average ± SD of 3 to 4 mice per group and 3 independent experiments. *P < 0.05.
Comment in
- Immunology. A chronic need for IL-21.
Johnson LD, Jameson SC. Johnson LD, et al. Science. 2009 Jun 19;324(5934):1525-6. doi: 10.1126/science.1176487. Science. 2009. PMID: 19541985 No abstract available.
Similar articles
- A vital role for interleukin-21 in the control of a chronic viral infection.
Yi JS, Du M, Zajac AJ. Yi JS, et al. Science. 2009 Jun 19;324(5934):1572-6. doi: 10.1126/science.1175194. Epub 2009 May 14. Science. 2009. PMID: 19443735 Free PMC article. - CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.
Matloubian M, Concepcion RJ, Ahmed R. Matloubian M, et al. J Virol. 1994 Dec;68(12):8056-63. doi: 10.1128/JVI.68.12.8056-8063.1994. J Virol. 1994. PMID: 7966595 Free PMC article. - A little 'help' from IL-21 during persistent viral infection.
McGavern DB. McGavern DB. J Mol Cell Biol. 2010 Feb;2(1):8-10. doi: 10.1093/jmcb/mjp021. Epub 2009 Oct 1. J Mol Cell Biol. 2010. PMID: 19797314 Free PMC article. - CD8 T cell dysfunction during chronic viral infection.
Shin H, Wherry EJ. Shin H, et al. Curr Opin Immunol. 2007 Aug;19(4):408-15. doi: 10.1016/j.coi.2007.06.004. Epub 2007 Jul 25. Curr Opin Immunol. 2007. PMID: 17656078 Review. - Induction and maintenance of CD8+ T cells specific for persistent viruses.
van Leeuwen EM, ten Berge IJ, van Lier RA. van Leeuwen EM, et al. Adv Exp Med Biol. 2007;590:121-37. doi: 10.1007/978-0-387-34814-8_9. Adv Exp Med Biol. 2007. PMID: 17191382 Review. No abstract available.
Cited by
- Differentiation and regulation of CD4+ T cell subsets in Parkinson's disease.
Sun X, Gu R, Bai J. Sun X, et al. Cell Mol Life Sci. 2024 Aug 17;81(1):352. doi: 10.1007/s00018-024-05402-0. Cell Mol Life Sci. 2024. PMID: 39153043 Free PMC article. Review. - Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression.
Costa JP, de Carvalho A, Paiva A, Borges O. Costa JP, et al. Pharmaceuticals (Basel). 2024 Jul 21;17(7):964. doi: 10.3390/ph17070964. Pharmaceuticals (Basel). 2024. PMID: 39065812 Free PMC article. Review. - T cell dysfunction and therapeutic intervention in cancer.
Zebley CC, Zehn D, Gottschalk S, Chi H. Zebley CC, et al. Nat Immunol. 2024 Aug;25(8):1344-1354. doi: 10.1038/s41590-024-01896-9. Epub 2024 Jul 18. Nat Immunol. 2024. PMID: 39025962 Review. - Stem-like T cells are associated with the pathogenesis of ulcerative colitis in humans.
Li Y, Ramírez-Suástegui C, Harris R, Castañeda-Castro FE, Ascui G, Pérez-Jeldres T, Diaz A, Morong C, Giles DA, Chai J, Seumois G, Sanchez-Elsner T, Cummings F, Kronenberg M, Vijayanand P. Li Y, et al. Nat Immunol. 2024 Jul;25(7):1231-1244. doi: 10.1038/s41590-024-01860-7. Epub 2024 Jun 19. Nat Immunol. 2024. PMID: 38898157 - Spontaneous immunological activities in the target tissue of vitiligo-prone Smyth and vitiligo-susceptible Brown lines of chicken.
Falcon DM, Byrne KA, Sales MA, Erf GF. Falcon DM, et al. Front Immunol. 2024 Apr 24;15:1386727. doi: 10.3389/fimmu.2024.1386727. eCollection 2024. Front Immunol. 2024. PMID: 38720888 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- R21 AI077012-03/AI/NIAID NIH HHS/United States
- R01 AI085043/AI/NIAID NIH HHS/United States
- U01 AI082975-01/AI/NIAID NIH HHS/United States
- R21 AI077012/AI/NIAID NIH HHS/United States
- AI082975/AI/NIAID NIH HHS/United States
- AI077012/AI/NIAID NIH HHS/United States
- U01 AI082975/AI/NIAID NIH HHS/United States
- AI070845/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous